Desoxycorticosterone Pivalate

Summary

Desoxycorticosterone Pivalate (CHEMBL1200592) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 414.6 Da · C26H38O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200592
Name	Desoxycorticosterone Pivalate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	11876263
ChEBI	CHEBI:50782
Molecular formula	C26H38O4
Molecular weight	414.6
InChIKey	VVOIQBFMTVCINR-WWMZEODYSA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)COC(=O)C(C)(C)C)CCC4=CC(=O)CC[C@]34C

IUPAC name: [2-[(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate

Also known as: Desoxycorticosterone pivalate, Desoxycorticosterone trimethylacetate, Desoxycortone pivalate, NSC-95278, Percorten, Zycortal, DESOXYCORTICOSTERONE PIVALATE, SID144205152, DESOXYCORTICOSTERONE-PIVALATE, desoxycorticosterone-pivalate, desoxycorticosterone pivalate

Patent coverage: 392 distinct patent families (1,232 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Glucocorticoid receptor, Progesterone receptor, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PGR	6.67	AC50	213	nM	CHEMBL_ACT_25222850
NR3C1	6.39	AC50	408	nM	CHEMBL_ACT_25175630

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).